Literature DB >> 16762931

Does a diagnosis of metabolic syndrome have value in clinical practice?

Scott M Grundy1.   

Abstract

"The metabolic syndrome" is the name for a clustering of risk factors for cardiovascular disease and type 2 diabetes that are of metabolic origin. These risk factors consist of atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, a prothrombotic state, and a proinflammatory state. There are 2 major, interacting causes of the metabolic syndrome-obesity and endogenous metabolic susceptibility. The latter typically is manifested by insulin resistance. The metabolic syndrome is accompanied by a 2-fold increase in the risk of cardiovascular disease and a 5-fold increase in the risk of type 2 diabetes. A clinical diagnosis of the metabolic syndrome is useful because it affects therapeutic strategy in patients at higher risk. However, there are 2 views about the best therapeutic strategy for patients with the metabolic syndrome. One view holds that each of the metabolic risk factors should be singled out and treated separately. The other view holds that greater emphasis should be given to implementing therapies that will reduce all of the risk factors simultaneously. The latter approach emphasizes lifestyle therapies (weight reduction and increased exercise), which target all of the risk factors. This approach is also the foundation of other therapies for targeting multiple risk factors together by striking at the underlying causes, as in the development of drugs to promote weight reduction and to reduce insulin resistance. Treating the underlying causes does not rule out the management of individual risk factors, but it will add strength to the control of multiple risk factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762931     DOI: 10.1093/ajcn/83.6.1248

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  28 in total

1.  Features of the metabolic syndrome in the Berlin Fat Mouse as a model for human obesity.

Authors:  Claudia Hantschel; Asja Wagener; Christina Neuschl; Daniel Teupser; Gudrun A Brockmann
Journal:  Obes Facts       Date:  2011-07-26       Impact factor: 3.942

2.  Knockout of SOD1 alters murine hepatic glycolysis, gluconeogenesis, and lipogenesis.

Authors:  Li Wang; Zongyong Jiang; Xin Gen Lei
Journal:  Free Radic Biol Med       Date:  2012-08-25       Impact factor: 7.376

3.  Anti-hyperglycemic and anti-hyperlipidemic potential of a polyherbal preparation "Diabegon" in metabolic syndrome subject with type 2 diabetes.

Authors:  Dhananjay Yadav; Arvind Tiwari; Meerambika Mishra; Senthil S Subramanian; Usha Singh Baghel; Sunil Mahajan; P S Bisen; G B K S Prasad
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-01-28

4.  The relationship of body fat to metabolic disease: influence of sex and ethnicity.

Authors:  Anne E Sumner
Journal:  Gend Med       Date:  2008-12

5.  Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zhiyuan Zhang; Thomas A Pearson; Lars Berglund
Journal:  Am J Cardiol       Date:  2010-11-01       Impact factor: 2.778

6.  Angiotensin receptor blockade recovers hepatic UCP2 expression and aconitase and SDH activities and ameliorates hepatic oxidative damage in insulin resistant rats.

Authors:  Priscilla Montez; José Pablo Vázquez-Medina; Rubén Rodríguez; Max A Thorwald; José A Viscarra; Lisa Lam; Janos Peti-Peterdi; Daisuke Nakano; Akira Nishiyama; Rudy M Ortiz
Journal:  Endocrinology       Date:  2012-10-18       Impact factor: 4.736

Review 7.  Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?

Authors:  Isabelle Lemieux; Paul Poirier; Jean Bergeron; Natalie Alméras; Benoît Lamarche; Bernard Cantin; Gilles R Dagenais; Jean-Pierre Després
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

8.  Angiotensin receptor and tumor necrosis factor-α activation contributes to glucose intolerance independent of systolic blood pressure in obese rats.

Authors:  Ruben Rodriguez; Andrew Lee; Keisa W Mathis; Hanna J Broome; Max Thorwald; Bridget Martinez; Daisuke Nakano; Akira Nishiyama; Michael J Ryan; Rudy M Ortiz
Journal:  Am J Physiol Renal Physiol       Date:  2018-07-11

9.  The role of nutrition therapy and dietitians in the management of the metabolic syndrome.

Authors:  Marion J Franz
Journal:  Curr Diab Rep       Date:  2007-02       Impact factor: 5.430

10.  A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components.

Authors:  Eusebio Chiefari; Sinan Tanyolaç; Stefania Iiritano; Angela Sciacqua; Carmelo Capula; Biagio Arcidiacono; Aurora Nocera; Katiuscia Possidente; Francesco Baudi; Valeria Ventura; Giuseppe Brunetti; Francesco S Brunetti; Raffaella Vero; Raffaele Maio; Manfredi Greco; Maria Pavia; Ugur Hodoglugil; Vincent Durlach; Clive R Pullinger; Ira D Goldfine; Francesco Perticone; Daniela Foti; Antonio Brunetti
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.